A citation-based method for searching scientific literature

J E Foley, M Ligueros-Saylan, Y-L He, J J Holst, C F Deacon, B E Dunning, A Leone-Jones, T Yu, D E Kelley. Horm Metab Res 2008
Times Cited: 33







List of co-cited articles
351 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Bo Ahrén, Anja Schweizer, Sylvie Dejager, Beth E Dunning, Peter M Nilsson, Margaretha Persson, James E Foley. J Clin Endocrinol Metab 2009
136
45

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
42

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Bo Ahrén, Mona Landin-Olsson, Per-Anders Jansson, Maria Svensson, David Holmes, Anja Schweizer. J Clin Endocrinol Metab 2004
517
36

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Julio Rosenstock, James E Foley, Marc Rendell, Mona Landin-Olsson, Jens J Holst, Carolyn F Deacon, Erika Rochotte, Michelle A Baron. Diabetes Care 2008
115
30

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Bogdan Balas, Muhammad R Baig, Catherine Watson, Beth E Dunning, Monica Ligueros-Saylan, Yibin Wang, Yan-Ling He, Celia Darland, Jens J Holst, Carolyn F Deacon,[...]. J Clin Endocrinol Metab 2007
181
27

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
27

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
27

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
A Mari, W M Sallas, Y L He, C Watson, M Ligueros-Saylan, B E Dunning, C F Deacon, J J Holst, J E Foley. J Clin Endocrinol Metab 2005
302
24

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
N Matikainen, S Mänttäri, A Schweizer, A Ulvestad, D Mills, B E Dunning, J E Foley, M-R Taskinen. Diabetologia 2006
246
24


Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
A J Garber, J E Foley, M A Banerji, P Ebeling, S Gudbjörnsdottir, R-P Camisasca, A Couturier, M A Baron. Diabetes Obes Metab 2008
168
24

Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Yan-Ling He, Yibin Wang, Julie M Bullock, Carolyn F Deacon, Jens Juul Holst, Beth E Dunning, Monica Ligueros-Saylan, James E Foley. J Clin Pharmacol 2007
77
24

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
24


Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
T Vilsbøll, J Rosenstock, H Yki-Järvinen, W T Cefalu, Y Chen, E Luo, B Musser, P J Andryuk, Y Ling, K D Kaufman,[...]. Diabetes Obes Metab 2010
235
24

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Johan Farngren, Margaretha Persson, Anja Schweizer, James E Foley, Bo Ahrén. J Clin Endocrinol Metab 2012
63
24

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Koichiro Azuma, Zofia Rádiková, Juliet Mancino, Frederico G S Toledo, Ernestine Thomas, Cyrous Kangani, Chiara Dalla Man, Claudio Cobelli, Jens J Holst, Carolyn F Deacon,[...]. J Clin Endocrinol Metab 2008
92
21


Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
W A Scherbaum, A Schweizer, A Mari, P M Nilsson, G Lalanne, Y Wang, B E Dunning, J E Foley. Diabetes Obes Metab 2008
86
21

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Kristina M Utzschneider, Jenny Tong, Brenda Montgomery, Jayalakshmi Udayasankar, Fernando Gerchman, Santica M Marcovina, Catherine E Watson, Monica A Ligueros-Saylan, James E Foley, Jens J Holst,[...]. Diabetes Care 2008
104
21

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Emanuele Bosi, Riccardo Paolo Camisasca, Carole Collober, Erika Rochotte, Alan J Garber. Diabetes Care 2007
329
21

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.
Andrea Mari, Werner A Scherbaum, Peter M Nilsson, Gerard Lalanne, Anja Schweizer, Beth E Dunning, Sophie Jauffret, James E Foley. J Clin Endocrinol Metab 2008
74
21

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
David A D'Alessio, Amanda M Denney, Linda M Hermiller, Ronald L Prigeon, Julie M Martin, William G Tharp, Monica Liqueros Saylan, Yanling He, Beth E Dunning, James E Foley,[...]. J Clin Endocrinol Metab 2009
70
21




Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
21

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
J Rosenstock, S W Kim, M A Baron, R-P Camisasca, F Cressier, A Couturier, S Dejager. Diabetes Obes Metab 2007
199
18

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
F Xavier Pi-Sunyer, Anja Schweizer, David Mills, Sylvie Dejager. Diabetes Res Clin Pract 2007
244
18

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
18

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
Michael Boschmann, Stefan Engeli, Kerstin Dobberstein, Petra Budziarek, Anke Strauss, Jana Boehnke, Fred C G J Sweep, Friedrich C Luft, Yanling He, James E Foley,[...]. J Clin Endocrinol Metab 2009
79
18

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
18



Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
B Ahrén, A Schweizer, S Dejager, E B Villhauer, B E Dunning, J E Foley. Diabetes Obes Metab 2011
97
18

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
18

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Kristine B Degn, Birgitte Brock, Claus B Juhl, Christian B Djurhuus, Jaime Grubert, Dennis Kim, Jenny Han, Kristin Taylor, Mark Fineman, Ole Schmitz. Diabetes 2004
198
15

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Andrea El-Ouaghlidi, Erika Rehring, Jens J Holst, Anja Schweizer, James Foley, David Holmes, Michael A Nauck. J Clin Endocrinol Metab 2007
91
15



Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.
Adrian Vella, Gerlies Bock, Paula D Giesler, Duane B Burton, Denise B Serra, Monica Ligueros Saylan, Beth E Dunning, James E Foley, Robert A Rizza, Michael Camilleri. Diabetes 2007
148
15

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.
W A Müller, G R Faloona, E Aguilar-Parada, R H Unger. N Engl J Med 1970
578
15

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Bo Ahrén, James E Foley, Ele Ferrannini, David R Matthews, Bernard Zinman, Sylvie Dejager, Vivian A Fonseca. Diabetes Care 2010
66
15



Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
15

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
172
15

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
120
15

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Julio Rosenstock, Michelle A Baron, Sylvie Dejager, David Mills, Anja Schweizer. Diabetes Care 2007
224
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.